Non-Cutaneous Melanoma — Research

Non-Cutaneous Melanoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	74	`("Non-Cutaneous Melanoma"[tiab] OR "Extracutaneous Melanoma"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	39	`("Non-Cutaneous Melanoma"[tiab] OR "Extracutaneous Melanoma"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	5	`("Non-Cutaneous Melanoma"[tiab] OR "Extracutaneous Melanoma"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 19 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (18)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 1–18 of 18 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
· J Clin Oncol · 2013 · PMID 23775962 · validated civic_curation pubmed
Prognostic parameters in uveal melanoma and their association with BAP1 expression.
· Br J Ophthalmol · 2014 · PMID 25147369 · validated civic_curation pubmed
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
· JAMA · 2014 · PMID 24938562 · validated civic_curation pubmed
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.